Pathfinder Cell Therapy, Inc. (PFND) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPathfinder Cell Therapy, Inc. (PFND) trades at $0.0001. Pathfinder Cell Therapy, Inc. is a development stage regenerative medicine company focusing on cell-derived therapies for diseases characterized by organ-specific cell damage. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for PFND: PFND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Pathfinder Cell Therapy, Inc. (PFND) Healthcare & Pipeline Overview
Pathfinder Cell Therapy, Inc., founded in 2008, is a development-stage biotech firm focused on regenerative medicine. The company is pioneering cell-derived therapies targeting diseases with organ-specific cell damage, including diabetes and cardiovascular conditions. It operates in the competitive biotechnology sector, facing established players and regulatory hurdles.
What Is the Investment Thesis for PFND?
Pathfinder Cell Therapy, Inc. presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's focus on cell-derived therapies targeting organ-specific cell damage addresses a significant unmet medical need. Successful development and commercialization of these therapies could generate substantial returns. However, the company faces significant challenges, including the lengthy and expensive regulatory approval process, the need for substantial capital investment, and competition from established pharmaceutical companies. The company's market capitalization is currently $0.00B, reflecting its development stage and the inherent risks associated with biotechnology investments. Key value drivers include successful completion of clinical trials, regulatory approvals, and strategic partnerships. Upcoming catalysts include the progression of its therapies through clinical trial phases.
Based on FMP financials and quantitative analysis
PFND Key Highlights
Pathfinder Cell Therapy, Inc. is a development stage company, focusing on novel cell-derived therapies.
- The company targets diseases characterized by organ-specific cell damage, including diabetes and cardiovascular conditions.
- The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
- The company's P/E ratio is -0.04, reflecting its current lack of profitability.
- The company has a beta of -24.33, indicating high volatility.
Who Are PFND's Competitors?
PFND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BITRF Biotron Limited | $0.02 | 0.00% | $19.4M | — |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PFND's Key Strengths?
Novel cell-derived therapy technology.
- Focus on regenerative medicine with high growth potential.
- Potential for strong intellectual property protection.
- Addresses unmet medical needs in specific disease indications.
What Are PFND's Weaknesses?
Development stage company with no current revenue.
- High dependence on research and development success.
- Limited financial resources and small team.
- Faces significant regulatory hurdles.
What Are the Key Risks for PFND?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trials and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Failure to secure funding for ongoing research.
- Technological obsolescence.
- Limited financial resources and small team.
What Are PFND's Competitive Advantages?
- Proprietary cell-derived therapy technology.
- Focus on specific disease indications with unmet medical needs.
- Potential for strong intellectual property protection through patents.
What Does PFND Do?
Pathfinder Cell Therapy, Inc., established in 2008, is a regenerative medicine company dedicated to developing innovative cell-derived therapies. The company's primary focus is on addressing diseases and medical conditions characterized by organ-specific cell damage. Pathfinder Cell Therapy identifies diabetes, renal disease, myocardial infarction, and peripheral vascular disease as potential indications for its technology. The company's research and development efforts are centered on creating therapies that can regenerate or repair damaged cells within specific organs, offering potential treatments for a range of debilitating conditions. Headquartered in Cambridge, Massachusetts, Pathfinder Cell Therapy operates as a development-stage company, meaning its primary activities revolve around research, preclinical studies, and clinical trials. As of 2026, the company has a small team of employees. Pathfinder Cell Therapy's success hinges on its ability to navigate the complex regulatory landscape, secure funding for ongoing research, and demonstrate the efficacy and safety of its cell-derived therapies in clinical trials.
What Products and Services Does PFND Offer?
- Develops cell-derived therapies for regenerative medicine.
- Targets diseases characterized by organ-specific cell damage.
- Focuses on indications like diabetes, renal disease, myocardial infarction, and peripheral vascular disease.
- Conducts research and preclinical studies to evaluate therapy efficacy.
- Seeks to regenerate or repair damaged cells within specific organs.
- Aims to provide potential treatments for debilitating conditions.
How Does PFND Make Money?
- Focuses on research and development of cell-derived therapies.
- Seeks to generate revenue through licensing agreements and partnerships.
- Aims to commercialize therapies upon successful clinical trials and regulatory approvals.
What Industry Does PFND Operate In?
Pathfinder Cell Therapy operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for growth. The regenerative medicine market, a subset of the biotechnology industry, is projected to experience substantial growth in the coming years, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes established pharmaceutical companies, as well as smaller biotechnology firms focused on regenerative medicine. Pathfinder Cell Therapy's success depends on its ability to differentiate its therapies, secure funding, and navigate the regulatory landscape.
Who Are PFND's Key Customers?
- Pharmaceutical companies seeking innovative therapies.
- Healthcare providers treating diseases with organ-specific cell damage.
- Patients suffering from diabetes, renal disease, myocardial infarction, and peripheral vascular disease.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Pathfinder Cell Therapy, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Richard L. Franklin. PFND has traded publicly since 2000.
Insider Activity
2 transactions · 0 purchases, 0 sales, 2 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Pathfinder Cell Therapy, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Pathfinder Cell Therapy, Inc. stands at 31.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
PFND Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PFND Latest News
-
Critical Analysis: Pathfinder Cell Therapy (OTCMKTS:PFND) and Nuvation Bio (NYSE:NUVB)
defenseworld.net · Aug 16, 2026
PFND Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PFND.
Price Targets
Wall Street price target analysis for PFND.
PFND MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PFND; grades run from A+ (80-100) to F (below 30).
Leadership: Richard L. Franklin
Managing
Richard L. Franklin is the managing employee of Pathfinder Cell Therapy, Inc. His leadership is crucial for guiding the company through its development stage and navigating the complexities of the biotechnology industry. His experience in regenerative medicine and cell-derived therapies, if any, would be a significant asset to the company.
Track Record: Due to the limited information available, it is difficult to assess Richard L. Franklin's track record at Pathfinder Cell Therapy, Inc. Key milestones and strategic decisions under his leadership are not publicly known. The company's progress in advancing its therapies through clinical trials and securing regulatory approvals will be a key indicator of his success.
PFND OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. These companies are not required to adhere to the same stringent reporting standards, making it difficult for investors to assess their financial health and operational performance. The OTC Other tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited or no financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Investigate the background of the company's management team.
- Attempt to obtain financial statements, even if not publicly available.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with the company's industry and operations.
- Consult with a financial advisor before investing.
- Be wary of unsolicited investment offers or guarantees of high returns.
- Company has been in operation since 2008.
- Focus on regenerative medicine, a growing field.
- Headquartered in Cambridge, Massachusetts, a biotech hub.
Common Questions About PFND (Healthcare)
What do analysts say about PFND stock?
As of 2026-03-16, there is no available analyst coverage for Pathfinder Cell Therapy, Inc. due to its OTC listing and development stage. Key valuation metrics such as price targets and earnings estimates are not available.
What are the main risks for PFND?
Pathfinder Cell Therapy, Inc. faces several significant risks inherent to its development stage and industry. These include the risk of unsuccessful clinical trials, which could halt the development of its therapies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and development stage.
- Financial data is limited and may not be up-to-date.
- Analyst coverage is non-existent.